The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing

키워드

참고문헌 (65)

1. Aisner DL, "Molecular pathology of non-small cell lung cancer : a practical guide", Am J Clin Pathol, 138, pp.332~346 (2012)
2. Allegrini S, "Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma", Am J Clin Pathol, 138, pp.377~381 (2012)
3. Dacic S, "Molecular genetic testing for lung adenocarcinomas : a practical approach to clinically relevant mutations and translocations", J Clin Pathol, 66, pp.870~874 (2013)
4. Knoepp SM, "Ancillary techniques on direct-smear aspirate slides : a significant evolution for cytopathology techniques", Cancer Cytopathol, 121, pp.120~128 (2013)
5. Roh MH, "Triage of cytologic direct smears for ancillary studies : a case-based illustration and review", Arch Pathol Lab Med, 137, pp.1185~1190 (2013)
6. Bellevicine C, "Epidermal growth factor receptor test performed on liquid-based cytology lung samples : experience of an academic referral center", Acta Cytol, 58, pp.589~594 (2014)
7. Bellevicine C, "EGFR analysis : current evidence and future directions", Diagn Cytopathol, 42, pp.984~992 (2014)
8. da Cunha Santos G, "EGFR mutations and lung cancer", Annu Rev Pathol, 6, pp.49~69 (2011)
9. Betz BL, "The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma", Am J Clin Pathol, 136, pp.564~571 (2011)
10. Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", J Mol Diagn, 15, pp.415~453 (2013)
11. Han JY, "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung", J Clin Oncol, 30, pp.1122~1128 (2012)
12. Katayama T, "Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study", Surg Oncol, 19, pp.e144~e149 (2010)
13. Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
14. Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
15. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
16. Zhang L, "Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic nonsmall-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial", Lancet Oncol, 13, pp.466~475 (2012)
17. Aisner DL, "The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities", Diagn Cytopathol, 40, pp.511~524 (2012)
18. Ellison G, "EGFR mutation testing in lung cancer : a review of available methods and their use for analysis of tumour tissue and cytology samples", J Clin Pathol, 66, pp.79~89 (2013)
19. Hookim K, "Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma", Cancer Cytopathol, 120, pp.52~61 (2012)
20. Chowdhuri SR, "EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection", Mod Pathol, 25, pp.548~555 (2012)
21. da Cunha Santos G, "EGFR gene status in cytological samples of nonsmall cell lung carcinoma : controversies and opportunities", Cancer Cytopathol, 119, pp.80~91 (2011)
22. Bernacki KD, "Molecular diagnostics of melanoma fine-needle aspirates : a cytology-histology correlation study", Am J Clin Pathol, 138, pp.670~677 (2012)
23. Killian JK, "Archival fine-needle aspiration cytopathology(FNAC)samples : untapped resource for clinical molecular profiling", J Mol Diagn, 12, pp.739~745 (2010)
24. Dejmek A, "Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality", Cancer Cytopathol, 121, pp.344~353 (2013)
25. Billah S, "EGFR and KRAS mutations in lung carcinoma : molecular testing by using cytology specimens", Cancer Cytopathol, 119, pp.111~117 (2011)
26. Boldrini L, "Mutational analysis in cytological specimens of advanced lung adenocarcinoma : a sensitive method for molecular diagnosis", J Thorac Oncol, 2, pp.1086~1090 (2007)
27. Bozzetti C, "Epidermal growth factor receptor and Kras gene expression : reliability of mutational analysis on cytological samples", Diagn Cytopathol, 41, pp.595~598 (2013)
28. Bruno P, "Reliability of direct sequencing of EGFR : comparison between cytological and histological samples from the same patient", Anticancer Res, 31, pp.4207~4210 (2011)
29. Khode R, "Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas", Cancer Cytopathol, 121, pp.361~369 (2013)
30. Lozano MD, "Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients : correlation with clinical outcomes", Oncologist, 16, pp.877~885 (2011)
31. Mitiushkina NV, "Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides", Cancer Cytopathol, 121, pp.370~376 (2013)
32. Nomoto K, "Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis", Am J Clin Pathol, 126, pp.608~615 (2006)
33. Pang B, "The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer : a single South East Asian laboratory’s analysis of 670 cases", Cytopathology, 23, pp.229~236 (2012)
34. Smith GD, "Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising highresolution melting amplicon analysis", J Clin Pathol, 61, pp.487~493 (2008)
35. Sun PL, "High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas", Cancer Cytopathol, 121, pp.311~319 (2013)
36. van Eijk R, "Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from nonsmall-cell lung cancer using allele-specific qPCR", PLoS One, 6, pp.e17791~ (2011)
37. Lee YS, "Computed tomography-guided transthoracic needle aspiration biopsy of intrapulmonary lesions: utility of a liquid-based cytopreparatory technique", Acta Cytol, 52, pp.665~670 (2008)
38. Malapelle U, "EGFR mutations detection on liquid-based cytology: is microscopy still necessary?", J Clin Pathol, 65, pp.561~564 (2012)
39. Malapelle U, "EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study", J Clin Pathol, 65, pp.87~91 (2012)
40. Reynolds JP, "EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration(FNA)at endobronchial ultrasound of non-small cell lung cancer(NSCLC)", Lung Cancer, 86, pp.158~163 (2014)
41. Sharma SV, "Epidermal growth factor receptor mutations in lung cancer", Nat Rev Cancer, 7, pp.169~181 (2007)
42. Ambrosini-Spaltro A, "EGFR mutation-specific antibodies in pulmonary adenocarcinoma : a comparison with DNA direct sequencing", Appl Immunohistochem Mol Morphol, 20, pp.356~362 (2012)
43. Brevet M, "Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR", J Mol Diagn, 12, pp.169~176 (2010)
44. Hasanovic A, "Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma", Lung Cancer, 77, pp.299~305 (2012)
45. Kato Y, "Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer : immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations", J Thorac Oncol, 5, pp.1551~1558 (2010)
46. Kitamura A, "Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer", Clin Cancer Res, 16, pp.3349~3355 (2010)
47. Kozu Y, "The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma", Lung Cancer, 73, pp.45~50 (2011)
48. Yu J, "Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer", Clin Cancer Res, 15, pp.3023~3028 (2009)
49. Rodig SJ, "Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population", Clin Cancer Res, 15, pp.5216~5223 (2009)
50. Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
51. Thunnissen E, "EML4-ALK testing in non-small cell carcinomas of the lung : a review with recommendations", Virchows Arch, 461, pp.245~257 (2012)
52. Camidge DR, "Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer : updated results from a phase 1 study", Lancet Oncol, 13, pp.1011~1019 (2012)
53. Betz BL, "The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma", Cancer Cytopathol, 121, pp.489~499 (2013)
54. Minca EC, "ALK status testing in nonsmall-cell lung carcinoma by FISH on ThinPrep slides with cytology material", J Thorac Oncol, 9, pp.464~468 (2014)
55. Neat MJ, "ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer", Cytopathology, 24, pp.356~364 (2013)
56. Proietti A, "Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer : comparison with histological assessment", Cancer Cytopathol, 122, pp.445~453 (2014)
57. Mino-Kenudson M, "A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry", Clin Cancer Res, 16, pp.1561~1571 (2010)
58. Savic S, "Detection of ALK-positive nonsmall-cell lung cancers on cytological specimens : high accuracy of immunocytochemistry with the 5A4 clone", J Thorac Oncol, 8, pp.1004~1011 (2013)
59. Bergethon K, "ROS1 rearrangements define a unique molecular class of lung cancers", J Clin Oncol, 30, pp.863~870 (2012)
60. Paik PK, "Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations", J Clin Oncol, 29, pp.2046~2051 (2011)
61. Luk PP, "BRAF mutations in non-small cell lung cancer", Transl Lung Cancer Res, 4, pp.142~148 (2015)
62. Gailey MP, "Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue", Cancer Cytopathol, 123, pp.30~39 (2015)
63. Hovelson DH, "Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors", Neoplasia, 17, pp.385~399 (2015)
64. Kanagal-Shamanna R, "Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples : promises and challenges for routine clinical diagnostics", Mod Pathol, 27, pp.314~327 (2014)
65. Karnes HE, "Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung", Cancer Cytopathol, 122, pp.104~113 (2014)

관련 논문AI추천